Another blood pressure medication recall has hit the market, this time from Legacy Pharmaceutical Packaging, LLC. The company has recalled 43 lots of repackaged Losartan tablets USP 25 mg, 50 mg, and 100 mg for a possible cancer-causing impurity.

Losartan Potassium USP tablets are used to treat high blood pressure and congestive heart failure. The recalled medication was packaged in 30 count bottles. NDC numbers include NDC 68645-577-54, NDC 68645-578-54, and NDC 68645-579-54, as well as NDC 68645-494-54.

A full list of recalled products can be found here and here.

The recall was issued after Camber Pharmaceuticals and Torrent Pharmaceuticals recalled Losartan tablets nationwide for trace amounts of N-Nitroso N-Methyl 4-amino butyric acid (NMBA) – a potential human carcinogen.

The recalled tablets were manufactured by Hetero Labs Limited. Legacy Pharmaceutical has not received any reports of adverse effects from the recall.

Consumers should return the recalled medication to their dispensing pharmacy.

For NDC numbers NDC 68645-577-54, NDC 68645-578-54, and NDC 68645-579-54, questions can be directed to Stericycle at 1-888-275-0506 from 9 a.m. to 5 p.m. CST, Monday through Friday.

For NDC number NDC 68645-494-54, questions can be directed to Inmar at 1-877-538-8443 from 9 a.m. to 5 p.m. EST, Monday through Friday.

Problems related to the recalled medication should be directed to a physician or healthcare provider.

Blood Pressure Recall 43 Lots Legacy Pharmaceutical Packaging has recalled 43 lots of 25 mg, 50 mg, and 100 mg Losartan Potassium tablets for a possible cancer-causing risk. Dr. Elizabeth Maziarka reads a blood pressure gauge during an examination of patient June Mendez at the Codman Square Health Center April 11, 2006 in Dorchester, Massachusetts. Massachusetts Governor Mitt Romney is scheduled to sign a health care reform bill April 12 that would make it the first state in the nation to require all its citizens have some form of health insurance. Photo: Getty Images/Joe Raedle